AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 152 min read$BIVI

BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

Original reporting
rttnews.com
Published Sep 15, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$BIVI
Bullish
high confidence
Mentioned
$BIVI
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

The data positions BioVie as a potential leader in this niche, but execution risk remains high.

02

Market read

First report of meaningful Phase 2 data for a Long COVID therapy; likely to move BIVI and influence related biotech stocks.

03

What to watch

Regulatory pathway and reimbursement landscape for Long COVID treatments remain uncertain.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Long COVID lacks approved therapies; biotech firms are racing to develop treatments.

Company-level read

Ticker impact

$BIVIBullishHigh confidence
Context

BioVie reported positive Phase 2 data for Bezisterim in Long COVID patients.

Expected impact

Potential short-term upside as traders price in Phase 3 prospects.

Evidence & confidence

First disclosure of robust Phase 2 data for a rare indication; market typically reacts positively to such milestones.

Market effects

Sector

Positive signal for the biotech sector focused on post‑viral syndromes and CNS‑active oral drugs.

Regional

May lift sentiment for U.S. small‑cap biotech stocks.

Global

Could attract interest from global investors tracking Long COVID therapeutics.

Counterpoint

What could challenge this read

Phase 2 success does not guarantee Phase 3 outcomes; investors may remain cautious.

Key entities

  • company
    BioVie Inc.

    NASDAQ‑listed biotech developing Bezisterim.

  • drug
    Bezisterim

    Oral candidate targeting inflammation and insulin sensitivity.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 26
$SPCXHighAI 8/10

MARKETS LIVE: Wall Street in the green as investors weigh Anthropic IPO filing

SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.

proactiveinvestors.com3 min
OCT 24
$BIVIMedAI 8/10

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.

finanznachrichten.de2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive Phase 2 Parkinson’s data for bezisterim

BioVie Inc. reported that its experimental Parkinson's drug, bezisterim, improved motor and non-motor symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD trial results. In the subgroup of 28 patients, those treated with bezisterim showed improvement, while placebo patients worsened slightly. Across all 57 patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo.

finance.yahoo.com2 min
OCT 20
$BIVIMedAI 8/10

BioVie reports positive bezisterim trial results in Parkinson’s

BioVie Inc. (BIVI) reported Phase 2 trial results for bezisterim in early-stage Parkinson’s patients. In a subgroup with high inflammation, bezisterim improved motor and non-motor scores versus placebo. Overall, bezisterim patients were 6.25x more likely to show meaningful improvement. Adverse events were lower in the treatment group. The trial enrolled untreated patients using a hybrid design. BioVie focuses on neurological and liver disease therapies.

investing.com2 min